Rinvoq (upadacitinib) receives U.S. FDA approval for giant cell arteritis – AbbVie
AbbVie announced the FDA has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the European Commission… read more.